Top 3 drug approvals in oncology in August: olaparib, capmatinib and momelotinib

In the latest instalment of our oncology drug approval round-up, read about a small selection of the promising approvals seen throughout August. Read this month’s edition to find out about a potential new standard of care drug for high-risk, early-stage breast cancer, as well as a differential JAK inhibitor (momelotinib) aiming to reduce symptoms of myelofibrosis. Lynparza® (olaparib) Approved: 4 August 2022 Approving body: EMA Indication: High-risk, early-stage breast cancer Following approval by the US FDA in March, olaparib has now been approved by the EMA (Amsterdam, Netherlands) for the treatment of patients with germline BRCA-mutated HER2-negative high-risk early-stage breast cancer....